knowledge -WSS

knowledge

author：comprehensive 2025-10-03 00:04:06 - browse：5965

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Biden's order seeks to regulate AI risk without stifling innovation

hotspot

WSS

The pink breast cancer awareness ribbon needs a redesign

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Digital health funding stays low as a new reality sets in

How are insurers handling Leqembi and related scans?

Physician subsidies by hospitals soar in wake of No Surprises Act

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Women's World Cup brings attention to abuse in soccer

Trump demands the U.S. pay no more for drugs than other countries … again

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Cancer drug shortages should be causing more outrage

Superbugs, antibiotic resistance get scrutiny in congress

Virginia high school admissions case could be legal follow

Britney Spears to release memoir, 'The Woman In Me,' later this year

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

hotspot

The pink breast cancer awareness ribbon needs a redesign

Digital health funding stays low as a new reality sets in

CDC recommends rationing of RSV shot due to shortages

Why Sanofi got shellacked over its spinoff

Medtronic CEO on promising devices for diabetes, hypertension

Chimpanzees, like humans and whales, get menopause: Study

hotspot

knowledge

focus

focus